PRESS RELEASE published on 06/03/2024 at 07:30, 2 years 3 months ago STS Group AG continues positive development with significant increase in sales revenue and earnings in the first quarter of 2024 STS Group AG reports a significant increase in sales revenue and earnings in the first quarter of 2024 despite economic challenges. Full-year guidance reaffirmed Sales Revenue Earnings First Quarter 2024 STS Group AG Full-year Guidance
PRESS RELEASE published on 06/03/2024 at 07:30, 2 years 3 months ago Mutares has successfully completed the acquisition of FSL Ladenbau GmbH Mutares SE & Co. KGaA successfully completes acquisition of FSL Ladenbau GmbH, a leading shopfitting provider in Northern Germany, strengthening Ganter Group with synergies and EUR 15 million in planned revenues for 2024 Acquisition Mutares SE & Co. KGaA FSL Ladenbau GmbH Ganter Group Shopfitting Provider
PRESS RELEASE published on 06/03/2024 at 07:30, 2 years 3 months ago Vallourec : André Lacerda est nommé Directeur Amérique du Sud (Activités Tubes) Vallourec nomme André Lacerda Directeur Amérique du Sud pour les activités Tubes. Expérience internationale solide et expertise en croissance et transformation Croissance Vallourec André Lacerda Directeur Amérique Du Sud Activités Tubes
PRESS RELEASE published on 06/03/2024 at 07:30, 2 years 3 months ago Transgene – Premier patient inclus dans la partie Phase II de l’étude randomisée de Phase I/II de son actif phare TG4050, un vaccin thérapeutique individualisé évalué dans les cancers de la tête et du cou Transgene annonce l'inclusion du premier patient dans la partie Phase II de l'étude randomisée de Phase I/II pour son vaccin TG4050 dans les cancers de la tête et du cou. Démarrage de la sélection des patients pour cette étude internationale Cancer De La Tête Et Du Cou Étude Clinique Transgene Vaccin Thérapeutique Néoantigènes
PRESS RELEASE published on 06/03/2024 at 07:30, 2 years 3 months ago Informations privilégiées / Autres communiqués GenSight Biologics nomme William Monteith à son Conseil d'administration. Monteith apportera son expertise en fabrication de thérapies géniques pour soutenir les progrès de l'entreprise Conseil D'administration Fabrication GenSight Biologics Thérapies Géniques William Monteith
PRESS RELEASE published on 06/03/2024 at 07:30, 2 years 3 months ago Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer Transgene enrolls first patient in Phase II of randomized Phase I/II trial for cancer vaccine TG4050 in head and neck cancer, with completion expected in Q4 2025 Phase II Trial Head And Neck Cancer Cancer Vaccine Transgene TG4050
PRESS RELEASE published on 06/03/2024 at 07:30, 2 years 3 months ago Number of voting rights as of May 31, 2024 Nicox SA monthly publication of the number of shares and voting rights. Details on market, ISIN code, and company's lead programs Voting Rights Shares Ophthalmology Monthly Publication Nicox SA
PRESS RELEASE published on 06/03/2024 at 07:30, 2 years 3 months ago Vallourec: Andre Lacerda Appointed Senior Vice President of South America (Tubes Activities) Vallourec appoints Andre Lacerda as Senior Vice President of South America for Tubes segment, bringing extensive international experience and market knowledge South America Senior Vice President Vallourec André Lacerda Tubes
PRESS RELEASE published on 06/03/2024 at 07:00, 2 years 3 months ago Relief Therapeutics Announces Executive Changes Relief Therapeutics announces executive changes as interim CEO Michelle Lock completes her mandate and transitions out, along with other key executives. Board to review management for optimal results Executive Changes Biopharmaceutical Relief Therapeutics Rare Diseases Management Review
PRESS RELEASE published on 06/03/2024 at 07:00, 2 years 3 months ago Orascom Development Holding AG: enters into an agreement for the sale of RAK Tourism Investment FZC in the UAE for a total enterprise value of USD 40 million Orascom Development Holding AG enters into a binding agreement to sell RAK Tourism Investment FZC in the UAE for USD 40 million. Transaction includes cash proceeds and debt assumption Sale Agreement Divestment Orascom Development Holding AG Enterprise Value RAK Tourism Investment FZC
Published on 09/12/2026 at 02:35, 1 day 2 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 6 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 8 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 12 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 11 hours 35 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 21 hours 55 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 7 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 7 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 9 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 1 day 22 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 22 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 2 days 9 hours ago Availability of the 2026 Interim Financial Report